Bhimanwar Rachana S, Mittal Amit, Chaudhari Snehal, Sharma Vikas
Department of Pharmaceutical Chemistry, Dr. D. Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri Pune Maharashtra-411018 India.
Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Lovely Professional University Jalandhar-Delhi G.T. Road (NH-1) Phagwara Punjab-144411 India
RSC Med Chem. 2024 Aug 7;15(9):3026-3037. doi: 10.1039/d4md00473f. eCollection 2024 Sep 19.
TGR5, a receptor that interacts with bile acids on cell surfaces, has become a promising therapeutic target for type II diabetes due to its ability to regulate energy expenditure and blood sugar levels. While several TGR5 agonists have been identified, only a few are currently in clinical trials. This article reviews the promising TGR5 agonists discovered in recent years, highlighting the chemical structure and pharmacological profile of the most effective compounds. With the limited number of effective drugs available for treating type II diabetes, the search for a potent TGR5 agonist with high efficacy and fewer side effects continues. The goal of this article is to provide an overview of the latest advancements in TGR5 agonists and offer insights for the future development of novel, potent TGR5 agonists for diabetes treatment. A noteworthy aspect addressed in the discussion is the common side effect associated with TGR5 agonist treatment - gallbladder filling. The review also explores potential strategies to mitigate this side effect, with the goal of improving the overall safety and tolerability of TGR5-targeted therapies.
TGR5是一种在细胞表面与胆汁酸相互作用的受体,由于其具有调节能量消耗和血糖水平的能力,已成为治疗II型糖尿病的一个有前景的治疗靶点。虽然已经鉴定出几种TGR5激动剂,但目前只有少数几种处于临床试验阶段。本文综述了近年来发现的有前景的TGR5激动剂,重点介绍了最有效化合物的化学结构和药理特性。由于治疗II型糖尿病的有效药物数量有限,寻找一种高效、副作用少的强效TGR5激动剂的工作仍在继续。本文的目的是概述TGR5激动剂的最新进展,并为新型强效TGR5激动剂用于糖尿病治疗的未来发展提供见解。讨论中涉及的一个值得注意的方面是与TGR5激动剂治疗相关的常见副作用——胆囊充盈。该综述还探讨了减轻这种副作用的潜在策略,目标是提高TGR5靶向治疗的整体安全性和耐受性。